Author:
Maiorano B.A.,De Giorgi U.,Roviello G.,Messina C.,Altavilla A.,Cattrini C.,Mennitto A.,Maiello E.,Di Maio M.
Reference29 articles.
1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022
2. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015
3. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016
4. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N Engl J Med,2017
5. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献